This Section is designed for healthcare professionals and GP Practice staff.

For public information, please visit the Brighton and Hove CCG public home page.

Patient Group Directions

Please see below for the current Patient Group Directions (PGDs) and a Template User Confirmation Document.

PGDs relative to Influenza vaccinations will be published and authorised as per usual timetabling ahead of the flu season.  For the updated Enhanced Service Specification detailing delivery of the Influenza programme, please see the GP Contract page of the NHS England website.

If you have any queries about the PGDs, please contact the Medicines Management Team

Template User Confirmation Document


The Template User Confirmation Document is for use by practice colleagues.

If you have any questions about this document, please contact us.

Chlamydia (Doxycycline)

The Patient Group Direction for Doxycycline is for use by clinicians.

If you have any questions about this document, please contact the Medicines Management Team

This PGD is for use in delivering the Young People's Sexual Health Locally Commissioned Service

Combined Low-Dose Diphtheria, Tetanus and Inactivated Polio Vaccine (Revaxis )

The Patient Group Direction for Combined Low-Dose Diphtheria, Tetanus and Inactivated Polio Vaccine (Revaxis ) is for use by clinicians.

If you have any questions about this document, please contact the Public Health England Immunisation Team

Diphtheria, Tetanus, Accelular Pertussis and Inactivated Poliomyelitis Vaccine (DTaP/IPV) (Infanrix-IPV or Repevax)

The Patient Group Direction for Diphtheria, Tetanus , Accelular Pertussis and Inactivated Poliomyelitis Vaccine (DTaP/IPV) (Infanrix-IPV or Repevax) is for use by clinicians.

If you have any questions about this document, please contact the Public Health England Immunisation Team

Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliomyelitis, Haemophilus Influenzae B, Hepatitis B (DTaP/IPV/Hib/HepB)

The Patient Group Direction for Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliomyelitis, Haemophilus Influenzae B, Hepatitis B is for use by clinicians.

The introduction of the hexavalent Vaccine is part of the routine immunisation programme (for babies born after August 1st 2017).

If you have any questions about this document, please contact the Public Health England Immunisation Team

Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliomyelitis, Haemophilus Influenzae B, (DTaP/IPV/Hib) Booster

The Patient Group Direction for Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliomyelitis, Haemophilus Influenzae B, (DTaP/IPV/Hib) Booster is for use by clinicians.

This new DTaP/IPV/Hib booster PGD allows for reallocation of DTAP/IPV/Hib vaccine stocks to be used for pre-school boosters, following the introduction of hexavalent vaccine DTAP/IPV/Hib/HepB into the routine infant immunisation program.

If you have any questions about this document, please contact the Public Health England Immunisation Team

Low Dose Diphtheria, Tetanus, Accelular Pertussis & Inactivated Poliomyelitis Vaccine (dTaP/IPV) (for women 16+ weeks pregnant)

The Patient Group Direction for Low Dose Diphtheria, Tetanus , Accelular Pertussis and Inactivated Poliomyelitis Vaccine (dTaP/IPV) (for women 16+ weeks pregnant) is for use by clinicians.

If you have any questions about this document, please contact the Public Health England Immunisation Team

Haemophilius Influenzae Type B and Meningococcal C (for patients with underlying medical conditions)

The Patient Group Direction for Haemophilius Influenzae Type B and Meningococcal C C (for patients with underlying medical conditions) is for use by clinicians.

If you have any questions about this document, please contact the Public Health England Immunisation Team

Haemophilius Influenzae Type B and Meningococcal C (as part of normal immunisation schedule)

The Patient Group Direction for Haemophilius Influenzae Type B and Meningococcal C (as part of normal immunisation schedule) is for use by clinicians.

If you have any questions about this document, please contact the Public Health England Immunisation Team

Hepatitis A Vaccine

The Patient Group Direction for Hepatitis A Vaccine is for use by clinicians.

If you have any questions about this document, please contact the Public Health England Immunisation Team

Hepatitis A and Typhoid Polysaccharide Vaccine (Hepatyrix or ViATIM)

The Patient Group Direction for Hepatitis A and Typhoid Polysaccharide Vaccine (Hepatyrix or ViATIM) is for use by clinicians.

If you have any questions about this document, please contact the Public Health England Immunisation Team

Hepatitis A Inactivated and Hepatitis B HAB rDNA Adsorbed

The Patient Group Direction for Hepatitis A Inactivated and Hepatitis B HAB rDNA Adsorbed is for use by clinicians.

If you have any questions about this document, please contact the Medicines Management Team

Hepatitis B rDNA Vaccine (for patients at increased risk)

The Patient Group Direction for Hepatitis B rDNA Vaccine (for patients at increased risk) is for use by clinicians.

If you have any questions about this document, please contact the Public Health England Immunisation Team

Hepatitis B rDNA Vaccine (for renal patients)

The Patient Group Direction for Hepatitis B rDNA Vaccine (for renal patients) is for use by clinicians.

If you have any questions about this document, please contact the Public Health England Immunisation Team

Human Papilloma Virus Vaccine (Gardasil)

The Patient Group Direction for Human Papilloma Virus Vaccine (Gardasil) is for use by clinicians.

If you have any questions about this document, please contact the Public Health England Immunisation Team

Levonorgestrel Emergency Hormonal Contraception (Levonelle 1500)

The Patient Group Direction for Levonorgestrel Emergency Hormonal Contraception (Levonelle 1500) is for use by clinicians.

This PGD is for use in delivering the Young People's Sexual Health Locally Commissioned Service.

If you have any questions about this document, please contact the Medicines Management Team

Influenza vaccine (intramuscular) Addendum

The Patient Group Direction for Influenza vaccine (intramuscular) Addendum is for use by clinicians.

If you have any questions about this document, please contact the Public Health England Immunisation Team

Influenza Vaccine (Intranasal) (Fluenz Tetra)

The Patient Group Direction for Influenza Vaccine (Intranasal) (Fluenz Tetra) is for use by clinicians.

If you have any questions about this document, please contact the Public Health England Immunisation Team

Measles, Mumps and Rubella Vaccine (M-M-Rvaxpro or Priorix)

The Patient Group Direction for Measles, Mumps and Rubella Vaccine (M-M-Rvaxpro or Priorix) is for use by clinicians.

If you have any questions about this document, please contact the Medicines Management Team

Meningococcal ACWY (for patients with underlying medical conditions)

The Patient Group Direction (PGDs) for Meningococcal ACWY Vaccine (for patients with underlying medical conditions)    

If you have any questions about this document, please contact the Public Health England Immunisation Team

Meningococcal ACWY (as part of normal immunisation schedule)

The Patient Group Direction (PGDs) for Meningococcal ACWY Vaccine (as part of normal immunisation schedule) is for use by practice colleagues.

If you have any questions about this document, please contact the Public Health England Immunisation Team

This PGD is for use in delivering the Meningococcal ACWY Direct Enhanced Service (DES).  You can find the Specification for this DES on the NHS England Website.

Meningococcal ACWY Correct Cohort document

The Meningococcal ACWY Correct Cohort document is for use by clinicians. It should be used in conjunction with the Meningococcal ACWY (as part of normal immunisation schedule) PGC

If you have any questions about this document, please contact the Public Health England Immunisation Team

Meningitis B Vaccine (for patients >2 years, with underlying medical condition which increases risk)

The Patient Group Direction for Meningitis B Vaccine (for patients >2 years, with underlying medical condition which increases risk) is for use by clinicians.

If you have any questions about this document, please contact the Public Health England Immunisation Team

Meningitis B Vaccine (for pts >8 weeks as part of the national imms program,& for prevention of 2°cases of Men B disease)

This PGD is for Meningitis B Vaccine

  • for patients > 8 weeks as part of the national routine immunisation program 
  • for individuals for the prevention of secondary cases of meningococcal group B disease

This Patient Group Direction is for use by clinicians.

If you have any questions about this document, please contact the Public Health England Immunisation Team

 

Nebulised Salbutamol

The Patient Group Direction for Nebulised Salbutamol is for use by clinicians.

If you have any questions about this document, please contact the Medicines Management Team

Pneumococcal Polysaccharide Conjugate Vaccine 13 Valent Adsorbed (Prevenar 13)

The Patient Group Direction for Pneumococcal Polysaccharide Conjugate Vaccine 13 Valent Adsorbed (Prevenar 13) is for use by clinicians.

If you have any questions about this document, please contact the Public Health England Immunisation Team

Pneumococcal Polysaccharide Conjugate Vaccine (for patients at increased risk)

The Patient Group Direction for Pneumococcal Polysaccharide Conjugate Vaccine (for patients at increased risk) is for use by clinicians.

If you have any questions about this document, please contact the Public Health England Immunisation Team

Pneumococcal Polysaccharide Vaccine (23-valent)


The Pneumococcal Polysaccharide Vaccine (23-valent) Patient Group Direction is for use by clinicians.

This document should be read in conjunction with the PGD for Administration of Immunisations by Healthcare Professionals above

If you have any questions about this document, please contact the Public Health England Immunisation Team

Rotavirus Vaccine Live (Rotarix Oral Suspension)

The Patient Group Direction for Rotavirus Vaccine Live (Rotarix Oral Suspension) is for use by clinicians.

If you have any questions about this document, please contact the Public Health England Immunisation Team

Salbutamol

The Patient Group Direction for Salbutamol via spacer device for the purpose of assessing bronchodilator reversibility and for post bronchodilator testing in spirometry is for use by clinicians.

If you have any questions about this document, please contact the Medicines Management Team

Shingles Vaccine (Zostavax)

The Patient Group Direction for Shingles Vaccine (Zostavax) is for use by clinicians.

If you have any questions about this document, please contact the Public Health England Immunisation Team

Typhoid Polysaccharide Vaccine

The Patient Group Direction for Typhoid Polysaccharide Vaccine is for use by clinicians.

If you have any questions about this document, please contact the Public Health England Immunisation Team

Ulipristal Acetate Emergency Hormonal Contraception (EllaOne)

The Patient Group Direction for Ulipristal Acetate Emergency Hormonal Contraception (EllaOne) is for use by clinicians.

This PGD is for use in delivering the Young People's Sexual Health Locally Commissioned Service.

If you have any questions about this document, please contact the Medicines Management Team

Varenicline: for use by Healthy Living Pharmacies

The Patient Group Direction for Varenicline is for use by clinicians in Healthy Living Pharmacies.

If you have any questions about this document, please contact us.